Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Simple and sensitive chromatographic method development for in-vitro and in-vivo analysis of doxorubicin-loaded poly lactic-co-glycolic acid nanoparticles

Sumaira Irum Khan, Zafar Iqbal , Fazli Nasir, Muhammad Ismail, Naila Shahbaz, Asma Khan, Muzna Ali Khattak, Mirina Sakhi

Department of Pharmacy, University of Peshawar, Peshawar 25120, Pakistan;

For correspondence:-  Zafar Iqbal   Email: zafar_iqbal@uop.edu.pk   Tel:+92919239619

Accepted: 19 October 2019        Published: 30 November 2019

Citation: Khan SI, Iqbal Z, Nasir F, Ismail M, Shahbaz N, Khan A, et al. Simple and sensitive chromatographic method development for in-vitro and in-vivo analysis of doxorubicin-loaded poly lactic-co-glycolic acid nanoparticles. Trop J Pharm Res 2019; 18(11):2415-2424 doi: 10.4314/tjpr.v18i11.27

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop a bioanalytical high performance liquid chromatography (HPLC) method for the quantification of doxorubicin in biological fluids and polymeric nano-formulations.
Methods: Analysis of doxorubicin in polymeric nanoparticles and biological samples was carried out at 252 nm using Purospher® RP-18 end-capped column (250mm×4.6mm,5µm) secured with a guard column cartridge RP18 (30mm×4.6mm,10µm). The mobile phase used was 0.025M phosphate buffer and acetonitrile (ACN) (65:35, v:v) in isocratic mode at a flow rate of 0.9 ml/min, run time of 10 min, column oven temperature of 30 °C, and injection volume of 40 μL.
Results: The standard curve for doxorubicin was linear (0.999) in the concentration range of 0.022 - 1.00 μg/mL in human and albino mice plasma. Nominal retention times of doxorubicin and IS were 3.5 and 5.5 min, respectively. Mean recovery was within acceptable limits (100 ± 2 %). The limit of detection (LOD) and limit of quantification (LOQ) were 0.012 and 0.022 μg/mL, respectively.
Conclusion: A reliable HPLC method has been successfully developed, validated and applied for the in vitro analysis of doxorubicin released from polymeric nanoparticles and in vivo pharmacokinetic studies in albino mice. The method may also be applicable to the analysis of doxorubicin in human fluids.

Keywords: RP-HPLC, Doxorubicin, Polymeric nanoparticles, Pharmacokinetics

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates